RxDoctor Payments Data

George Cain, MD

Family Medicine · Corinth, MSNPI 1790709079

Payments from drug & device makers

$782in general payments, 2019–2025

Across 34 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$407
  • Astellas Pharma US Inc$85
  • Sunovion Pharmaceuticals Inc.$62
  • Johnson & Johnson$58
  • Kowa Pharmaceuticals America, Inc.$41
  • Otsuka America Pharmaceutical, Inc.$36
  • plus $93 from 6 others

What the payments were for

  • Food & beverage$69789%
  • Education$8511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$782 in reported general payments places this provider in the 55th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$216,437
Medicare patients
492
Services billed
9,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban209$67,581
OzempicSemaglutide51$50,212
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$48,623
JardianceEmpagliflozin74$31,429
XareltoRivaroxaban69$24,363
FarxigaDapagliflozin Propanediol73$21,154
JanuviaSitagliptin Phosphate43$18,807
TrulicityDulaglutide17$17,257
LinzessLinaclotide30$15,630
MyrbetriqMirabegron53$14,864
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$14,077
Combivent RespimatIpratropium/Albuterol Sulfate15$12,951
BrilintaTicagrelor29$11,485
Bydureon BciseExenatide Microspheres11$9,766
TradjentaLinagliptin24$6,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$50,21251 claims
Johnson & JohnsonXarelto$58$24,36369 claims
AbbVieLinzess$407$15,63030 claims
Astellas Pharma US IncMyrbetriq$85$14,86453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Corinth

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →